A guaranteed purchase prize for the first drug against a named hard target
Governments promised in advance to buy vaccines that did not yet exist, and they got made. The same promise could be made for a drug against a target everyone has given up on.
Advance market commitments worked for pneumococcal vaccines and shaped COVID-19 vaccine supply. Applied to undruggable oncology targets, a public or philanthropic funder would commit to purchase a defined volume at a defined price for the first agent meeting a pre-specified efficacy bar against a designated target such as KRAS G12D in pancreatic cancer or gain-of-function mutant p53, with access conditions attached.
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
Pages like this
not linked directly; found by shared links- IdeaCure-focused prizes: pay for verified long-term cures, not for drugs
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains, Pancreatic ductal adenocarcinoma.
- IdeaMilestone prizes for first-in-class mechanisms reaching human proof of concept
Shares Incentives reward me-too drugs and marginal gains, TP53, KRAS, The undruggable drivers.
- ProductMRTX1133
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares KRAS, The undruggable drivers.
- TrialCodeBreaK 200
Shares KRAS, The undruggable drivers.
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares TP53, The undruggable drivers.
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaExtend p53 reactivation beyond the Y220C mutation
Shares TP53, The undruggable drivers.